Royal Prima PT (PRIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Royal Prima PT (PRIM) has a cash flow conversion efficiency ratio of 0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp1.86 Billion ≈ $108.71K USD) by net assets (Rp955.60 Billion ≈ $55.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Royal Prima PT - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Royal Prima PT's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PRIM total debt and obligations for a breakdown of total debt and financial obligations.
Royal Prima PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Royal Prima PT ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pineapple Financial Inc.
NYSE MKT:PAPL
|
0.089x |
|
BR.SCH.ED.HLD.SP.ADR CL.A
F:BSK0
|
N/A |
|
Enzo Biochem Inc
NYSE:ENZ
|
-0.074x |
|
Genenta Science SpA ADR
NASDAQ:GNTA
|
0.000x |
|
Tasman Resources Ltd
AU:TAS
|
-0.077x |
|
Indbank Merchant Banking Services Limited
NSE:INDBANK
|
-0.033x |
|
ViroGates A/S
CO:VIRO
|
-0.879x |
|
Maheshwari Logistics Limited
NSE:MAHESHWARI
|
-0.136x |
Annual Cash Flow Conversion Efficiency for Royal Prima PT (2014–2024)
The table below shows the annual cash flow conversion efficiency of Royal Prima PT from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Royal Prima PT.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp962.38 Billion ≈ $56.39 Million |
Rp46.98 Billion ≈ $2.75 Million |
0.049x | +125.21% |
| 2023-12-31 | Rp981.10 Billion ≈ $57.49 Million |
Rp21.27 Billion ≈ $1.25 Million |
0.022x | -1.33% |
| 2022-12-31 | Rp982.66 Billion ≈ $57.58 Million |
Rp21.59 Billion ≈ $1.27 Million |
0.022x | -90.97% |
| 2021-12-31 | Rp964.21 Billion ≈ $56.50 Million |
Rp234.54 Billion ≈ $13.74 Million |
0.243x | +259.56% |
| 2020-12-31 | Rp889.35 Billion ≈ $52.11 Million |
Rp60.16 Billion ≈ $3.53 Million |
0.068x | +1830.15% |
| 2019-12-31 | Rp851.17 Billion ≈ $49.88 Million |
Rp2.98 Billion ≈ $174.81K |
0.004x | -91.58% |
| 2018-12-31 | Rp848.87 Billion ≈ $49.74 Million |
Rp35.33 Billion ≈ $2.07 Million |
0.042x | -53.08% |
| 2017-12-31 | Rp250.42 Billion ≈ $14.67 Million |
Rp22.22 Billion ≈ $1.30 Million |
0.089x | -96.16% |
| 2016-12-31 | Rp12.13 Billion ≈ $710.64K |
Rp28.02 Billion ≈ $1.64 Million |
2.310x | +135.31% |
| 2015-12-31 | Rp722.89 Million ≈ $42.36K |
Rp-4.73 Billion ≈ $-277.14K |
-6.543x | -274.24% |
| 2014-12-31 | Rp-2.10 Billion ≈ $-123.29K |
Rp3.68 Billion ≈ $215.54K |
-1.748x | -- |
About Royal Prima PT
PT Royal Prima Tbk engages in providing hospital services in Indonesia. The company operates its hospitals under the Royal Prima Medan, Royal Prima Jambi, and RSU Royal Prima Marelan names. It provides health services, such as emergency, outpatient, inpatient, laboratorium, radiology, medical rehab, pharmacy, and MCU; and general surgery, internist, VCT, ICU, cardiology, urology, haemodialysis, m… Read more